Nononcological applications of positron emission tomography for evaluation of the thorax

Journal of Thoracic Imaging

Volumn 28, Issue 1, 2013, Pages 25-39

  Kwee, Thomas C ^a   Torigian, Drew A ^b   Alavi, Abass ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

18F fluoro 2 deoxy D glucose; atherosclerosis; brown fat; infection; inflammation; positron emission tomography; thorax

Indexed keywords

ANTIBIOTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ACTINOMYCOSIS; ADULT RESPIRATORY DISTRESS SYNDROME; ANTIBIOTIC THERAPY; ASPERGILLOSIS; ATHEROSCLEROSIS; BACTERIAL ENDOCARDITIS; BACTERIAL PNEUMONIA; BROWN ADIPOSE TISSUE; CANDIDIASIS; CATHETER INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; FORCED EXPIRATORY VOLUME; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPLASMOSIS; HUMAN; INFECTION; INTERSTITIAL PNEUMONIA; LUNG ABSCESS; LUNG HYDATID CYST; MOLECULAR IMAGING; MULTIPLE MYELOMA; NEUTROPENIA; OSTEOMYELITIS; PNEUMOCYSTIS PNEUMONIA; POSITRON EMISSION TOMOGRAPHY; PYREXIA IDIOPATHICA; RADIATION DOSE; REVIEW; SARCOIDOSIS; SENSITIVITY AND SPECIFICITY; VENOUS THROMBOEMBOLISM;

ATHEROSCLEROSIS; FLUORODEOXYGLUCOSE F18; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; INFECTION; POSITRON-EMISSION TOMOGRAPHY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RADIOPHARMACEUTICALS; RESPIRATORY DISTRESS SYNDROME, ADULT; SARCOIDOSIS; THORACIC DISEASES; THORAX;

EID: 84871745599     PISSN: 08835993     EISSN: 15360237     Source Type: Journal    
DOI: 10.1097/RTI.0b013e31827882a9     Document Type: Review

References (103)

1. Margulis AR. Molecular imaging: love it or lose it. Radiology. 2012;264:5.
2. Margolis DJ, Hoffman JM, Herfkens RJ, et al. Molecular imaging techniques in body imaging. Radiology. 2007;245: 333-356.
3. Alavi A, Gupta N, Alberini JL, et al. Positron emission tomography imaging in nonmalignant thoracic disorders. Semin Nucl Med. 2002;32:293-321.
4. Liu Y. Demonstrations of AIDS-associated malignancies and infections at FDG PET-CT. Ann Nucl Med. 2011;25:536-546.
5. Jones HA, Clark RJ, Rhodes CG, et al. in vivo measurement of neutrophil activity in experimental lung inflammation. Am J Respir Crit Care Med. 1994;149:1635-1639.
6. Kapucu LO, Meltzer CC, Townsend DW, et al. Fluorine-18-fluorodeoxyglucose uptake in pneumonia. J Nucl Med. 1998;39:1267-1269.
7. Bakheet SM, Saleem M, Powe J, et al. F-18 fluorodeoxyglucose chest uptake in lung inflammation and infection. Clin Nucl Med. 2000;25:273-278.
8. Mahfouz T,Miceli MH, Saghafifar F, et al. 18F-fluorodeoxyglucose positron emission tomography contributes to the diagnosis and management of infections in patients with multiple myeloma: a study of 165 infectious episodes. J Clin Oncol. 2005;23:7857-7863.
9. Martinez V, Castilla-Lievre MA, Guillet-Caruba C, et al. (18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response. Int J Tuberc Lung Dis. 2012; 16:1180-1185.
10. Franzius C, Biermann M, Hülskamp G, et al. Therapy monitoring in aspergillosis using F-18 FDG positron emission tomography. Clin Nucl Med. 2001;26:232-233.
11. Win Z, Todd J, Al-Nahhas A. FDG-PET imaging in Pneumocystis carinii pneumonia. Clin Nucl Med. 2005;30:690-691.
12. Reuter S, Schirrmeister H, Kratzer W, et al. Pericystic metabolic activity in alveolar echinococcosis: assessment and follow-up by positron emission tomography. Clin Infect Dis. 1999;29:1157-1163.
13. Vos FJ, Donnelly JP, Oyen WJ, et al. 18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. Eur J Nucl Med Mol Imaging. 2012;39:120-128.
14. Keidar Z, Gurman-Balbir A, Gaitini D, et al. Fever of unknown origin: the role of 18F-FDG PET/CT. J Nucl Med. 2008;49:1980-1985.
15. Dong MJ, Zhao K, Liu ZF, et al. A meta-analysis of the value of fluorodeoxyglucose-PET/PET-CT in the evaluation of fever of unknown origin. Eur J Radiol. 2011;80:834-844.
16. Moghadam-Kia S, Nawaz A, Millar BC, et al. Imaging with (18)F-FDG-PET in infective endocarditis: promising role in difficult diagnosis and treatment monitoring. Hell J Nucl Med. 2009;12:165-167.
17. Yen RF, Chen YC, Wu YW, et al. Using 18-fluoro-2-deoxyglucose positron emission tomography in detecting infectious endocarditis/endoarteritis: a preliminary report. Acad Radiol. 2004;11:316-321.
18. Millar BC, Prendergast BD, Alavi A, et al. Positron emission tomography (PET): a new tool in the diagnosis of endocarditis. Heart. 2009;95:332-333.
19. Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364: 369-379.
20. Termaat MF, Raijmakers PG, Scholten HJ, et al. The accuracy of diagnostic imaging for the assessment of chronic osteomyelitis: a systematic review and meta-analysis. J Bone Joint Surg Am. 2005;87:2464-2471.
21. Wang GL, Zhao K, Liu ZF, et al. A meta-analysis of fluorodeoxyglucose- positron emission tomography versus scintigraphy in the evaluation of suspected osteomyelitis. Nucl Med Commun. 2011;32:1134-1142.
22. Nawaz A, Torigian DA, Siegelman ES, et al. Diagnostic performance of FDG-PET, MRI, and plain film radiography (PFR) for the diagnosis of osteomyelitis in the diabetic foot. Mol Imaging Biol. 2010;12:335-342.
23. Kagna O, Srour S, Melamed E, et al. FDG PET/CT imaging in the diagnosis of osteomyelitis in the diabetic foot. Eur J Nucl Med Mol Imaging. 2012;39:1545-1550.
24. Wilkoff BL, Love CJ, Byrd CL, et al. Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA). Heart Rhythm. 2009;6:1085-1104.
25. Baddour LM, Epstein AE, Erickson CC, et al. American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee; Council on Cardiovascular Disease in Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Nursing; Council on Clinical Cardiology; Interdisciplinary Council on Quality of Care; American Heart Association. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation. 2010;121:458-477.
26. Bensimhon L, Lavergne T, Hugonnet F, et al. Whole body [(18) F]fluorodeoxyglucose positron emission tomography imaging for the diagnosis of pacemaker or implantable cardioverter defibrillator infection: a preliminary prospective study. Clin Microbiol Infect. 2011;17:836-844.
27. Sarrazin JF, Philippon F, TessierM, et al. Usefulness of fluorine-18 positron emission tomography/computed tomography for identification of cardiovascular implantable electronic device infections. J Am Coll Cardiol. 2012;59:1616-1625.
28. Miceli MH, Jones Jackson LB, Walker RC, et al. Diagnosis of infection of implantable central venous catheters by [18F]fluorodeoxyglucose positron emission tomography. Nucl Med Commun. 2004;25:813-818.
29. Iannuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. N Engl J Med. 2007;357:2153-2165.
30. Treglia G, Taralli S, Giordano A. Emerging role of wholebody 18F-fluorodeoxyglucose positron emission tomography as a marker of disease activity in patients with sarcoidosis: a systematic review. Sarcoidosis Vasc Diffuse Lung Dis. 2011;28:87-94.
31. Mañ á J, Gámez C. Molecular imaging in sarcoidosis. Curr Opin Pulm Med. 2011;17:325-331.
32. Sobic-Saranovic D, Grozdic I, Videnovic-Ivanov J, et al. The utility of 18F-FDG PET/CT for diagnosis and adjustment of therapy in patients with active chronic sarcoidosis. J Nucl Med. 2012;53:1543-1549.
33. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med. 2012;53:241-248.
34. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277-304.
35. Mueller-Mang C, Grosse C, Schmid K, et al. What every radiologist should know about idiopathic interstitial pneumonias. Radiographics. 2007;27:595-615.
36. Lynch DA, Travis WD,Müller NL, et al. Idiopathic interstitial pneumonias: CT features. Radiology.236:; 2005:10-21.
37. Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824.
38. Meissner HH, Soo Hoo GW, Khonsary SA, et al. Idiopathic pulmonary fibrosis: evaluation with positron emission tomography. Respiration. 2006;73:197-202.
39. Groves AM,Win T, Screaton NJ, et al. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT. J Nucl Med. 2009;50:538-545.
40. Inoue K, Okada K, Taki Y, et al. (18)FDG uptake associated with CT density on PET/CT in lungs with and without chronic interstitial lung diseases. Ann Nucl Med. 2009;23:277-281.
41. Thomeer M, Grutters JC, Wuyts WA, et al. Clinical use of biomarkers of survival in pulmonary fibrosis. Respir Res. 2010;11:1-7.
42. Win T, Lambrou T, Hutton BF, et al. 18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials. Eur J Nucl Med Mol Imaging. 2012;39:521-528.
43. Chong S, Lee KS, Chung MJ, et al. Pneumoconiosis: comparison of imaging and pathologic findings. Radiographics. 2006;26:59-77.
44. Basu S, Alavi A. Avid FDG uptake in the right ventricle coupled with enhanced intercostal muscle hypermetabolism in pneumoconiosis. Clin Nucl Med. 2007;32:407-408.
45. Basu S, Alzeair S, Li G, et al. Etiopathologies associated with intercostal muscle hypermetabolism and prominent right ventricle visualization on 2-deoxy-2[F-18]fluoro-D-glucosepositron emission tomography: significance of an incidental finding and in the setting of a known pulmonary disease. Mol Imaging Biol. 2007;9:333-339.
46. Reichert M, Bensadoun ES. PET imaging in patients with coal workers pneumoconiosis and suspected malignancy. J Thorac Oncol. 2009;4:649-651.
47. Chung SY, Lee JH, Kim TH, et al. 18F-FDG PET imaging of progressive massive fibrosis. Ann Nucl Med. 2010;24:21-27.
48. Saydam O, Gokce M, Kilicgun A, et al. Accuracy of positron emission tomography in mediastinal node assessment in coal workers with lung cancer. Med Oncol. 2012;29:589-594.
49. Kanegae K, Nakano I, Kimura K, et al. Comparison of MET-PET and FDG-PET for differentiation between benign lesions and lung cancer in pneumoconiosis. Ann Nucl Med. 2007;21:331-337.
50. Kim BS, Kim IJ, Kim SJ, et al. Predictive value of F-18 FDG PET/CT for malignant pleural effusion in non-small cell lung cancer patients. Onkologie. 2011;34:298-303.
51. Alkhawaldeh K, Biersack HJ, Henke A, et al. Impact of dualtime-point F-18 FDG PET/CT in the assessment of pleural effusion in patients with non-small-cell lung cancer. Clin Nucl Med. 2011;36:423-428.
52. De Prost N, Tucci MR, Melo MF. Assessment of lung inflammation with 18F-FDG PET during acute lung injury. Am J Roentgenol. 2010;195:292-300.
53. Chen DL, Schuster DP. Positron emission tomography with [18F]fluorodeoxyglucose to evaluate neutrophil kinetics during acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2004;286:L834-L840.
54. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet. 2012;379:1341-1351.
55. Jones HA, Marino PS, Shakur BH, et al. In vivo assessment of lung inflammatory cell activity in patients with COPD and asthma. Eur Respir J. 2003;21:567-573.
56. Subramanian DR, Jenkins L, Edgar R, et al. Assessment of pulmonary neutrophilic inflammation in emphysema by quantitative positron emission tomography. Am J Respir Crit CareMed.
57. 2012. [Epub ahead of print] doi: 10.1164/rccm.201201-0051OC.
58. Coulson JM, Rudd JH, Duckers JM, et al. Excessive aortic inflammation in chronic obstructive pulmonary disease: an 18F-FDG PET pilot study. J Nucl Med. 2010;51:1357-1360.
59. Aydin A, Hickeson M, Yu JQ, et al. Demonstration of excessive metabolic activity of thoracic and abdominal muscles on FDG-PET in patients with chronic obstructive pulmonary disease. Clin Nucl Med. 2005;30:159-164.
60. Osman MM, Tran IT, Muzaffar R, et al. Does 18F-FDG uptake by respiratory muscles on PET/CT correlate with chronic obstructive pulmonary disease? J Nucl Med Technol. 2011;39:252-257.
61. Vidal Melo MF, Winkler T, Harris RS, et al. Spatial heterogeneity of lung perfusion assessed with (13)N PET as a vascular biomarker in chronic obstructive pulmonary disease. J Nucl Med. 2010;51:57-65.
62. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373:1891-1904.
63. Amin R, Charron M, Grinblat L, et al. Cystic fibrosis: detecting changes in airway inflammation with FDG PET/CT. Radiology. 2012;264:868-875.
64. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
65. Majmudar MD, Nahrendorf M. Cardiovascular molecular imaging: the road ahead. J Nucl Med. 2012;53:673-676.
66. Roivainen A, Jalkanen S, Nanni C. Gallium-labelled peptides for imaging of inflammation. Eur J Nucl Med Mol Imaging. 2012;39(suppl 1):S68-S77.
67. Perrone-Filardi P, Dellegrottaglie S, Rudd JH, et al. Molecular imaging of atherosclerosis in translational medicine. Eur J Nucl Med Mol Imaging. 2011;38:969-975.
68. Chen W, Bural GG, Torigian DA, et al. Emerging role of FDG-PET/CT in assessing atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. 2009;36:144-151.
69. Bural GG, Torigian DA, Chamroonrat W, et al. FDG-PET is an effective imaging modality to detect and quantify agerelated atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging. 2008;35:562-569.
70. Mehta NN, Yu Y, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]- fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol. 2011;147:1031-1039.
71. Rudd JH, Myers KS, Bansilal S, et al. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med. 2008;49:871-878.
72. Cheng VY, Slomka PJ, Le Meunier L, et al. Coronary arterial 18F-FDG uptake by fusion of PET and coronary CT angiography at sites of percutaneous stenting for acute myocardial infarction and stable coronary artery disease. J Nucl Med. 2012;53:575-583.
73. Basu S, Høilund-Carlsen PF, Alavi A. Assessing global cardiovascular molecular calcification with 18F-fluoride PET/CT: will this become a clinical reality and a challenge to CT calcification scoring? Eur J Nucl Med Mol Imaging. 2012;39:660-664.
74. Derlin T, Richter U, Bannas P, et al. Feasibility of 18Fsodium fluoride PET/CT for imaging of atherosclerotic plaque. J Nucl Med. 2010;51:862-865.
75. Saboury B, Ziai P, Alavi A. Detection and quantification of molecular calcification by PET/computed tomography: a new paradigm in assessing atherosclerosis. PET Clin. 2011; 6:409-415.
76. Beheshti M, Saboury B, Mehta NN, et al. Detection and global quantification of cardiovascular molecular calcification by fluoro18-fluoride positron emission tomography/computed tomography-a novel concept. Hell J Nucl Med. 2011;14:114-120.
77. Derlin T, Toth Z, Papp L, et al. Correlation of inflammation assessed by 18F-FDG PET, active mineral deposition assessed by 18F-fluoride PET, and vascular calcification in atherosclerotic plaque: a dual-tracer PET/CT study. J Nucl Med. 2011;52:1020-1027.
78. Li Y, Berenji GR, Shaba WF, et al. Association of vascular fluoride uptake with vascular calcification and coronary artery disease. Nucl Med Commun. 2012;33:14-20.
79. Dweck MR, Chow MW, Joshi NV, et al. Coronary arterial 18F-sodium fluoride uptake: a novel marker of plaque biology. J Am Coll Cardiol. 2012;59:1539-1548.
80. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379:1835-1846.
81. Sydow BD, Srinivas SM, Newberg A, et al. Deep venous thrombosis on F-18 FDG PET/CT imaging. Clin Nucl Med. 2006;31:403-404.
82. Capete-Sanchez FM, Gandhi M, Evans TL, et al. Detection by 18F-FDG-PET/CT of upper extremity acute deep venous thrombosis. Hell J Nucl Med. 2011;14:81-82.
83. Wittram C, Scott JA. 18F-FDG PET of pulmonary embolism. Am J Roentgenol. 2007;189:171-176.
84. Sharma P, Kumar R, Singh H, et al. Imaging thrombus in cancer patients with FDG PET-CT. Jpn J Radiol. 2012;30:95-104.
85. Slart RH, Bax JJ, van Veldhuisen DJ, et al. Imaging techniques in nuclear cardiology for the assessment of myocardial viability. Int J Cardiovasc Imaging. 2006;22:63-80.
86. Donswijk ML, Broekhuizen-de Gast HS, Torigian DA, et al. PET assessment of brown fat. PET Clin. 2011;6:365-375.
87. Kajimura S, Seale P, Spiegelman BM. Transcriptional control of brown fat development. Cell Metab. 2010;11:257-262.
88. Delbeke D, Coleman RE, Guiberteau MJ, et al. Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. J Nucl Med. 2006;47:885-895.
89. Willowson KP, Bailey EA, Bailey DL. A retrospective evaluation of radiation dose associated with low dose FDG protocols in whole-body PET/CT. Australas Phys Eng Sci Med. 2012;35:49-53.
90. Brix G, Lechel U, Glatting G, et al. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations. J Nucl Med. 2005;46:608-613.
91. Huang B, Law MW, Khong PL. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology. 2009;251:166-174.
92. Murano T, Minamimoto R, Senda M, et al. Radiation exposure and risk-benefit analysis in cancer screening using FDG-PET: results of a Japanese nationwide survey. Ann Nucl Med. 2011;25:657-666.
93. Smith-Bindman R, Lipson J, Marcus R, et al. Radiation dose associated with common computed tomography examinations and the associated lifetime attributable risk of cancer. Arch Intern Med. 2009;169:2078-2086.
94. Sodickson A, Baeyens PF, Andriole KP, et al. Recurrent CT, cumulative radiation exposure, and associated radiationinduced cancer risks from CT of adults. Radiology. 2009; 251:175-184.
95. Conti M. Focus on time-of-flight PET: the benefits of improved time resolution. Eur J Nucl Med Mol Imaging. 2011;38:1147-1157.
96. Boellaard R, O'Doherty MJ, Weber WA, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181-200.
97. Katsura M, Matsuda I, Akahane M, et al. Model-based iterative reconstruction technique for radiation dose reduction in chest CT: comparison with the adaptive statistical iterative reconstruction technique. Eur Radiol. 2012;22:1613-1623.
98. Singh S, Kalra MK, Do S, et al. Comparison of hybrid and pure iterative reconstruction techniques with conventional filtered back projection: dose reduction potential in the abdomen. J Comput Assist Tomogr. 2012;36:347-353.
99. Petrausch U, Samaras P, Haile SR, et al. Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy. Ann Oncol. 2010; 21:1694-1698.
100. Hardin LV, Ravenel J, Gordon L, et al. Radiation risks to lymphoma patients undergoing 18F-FDG studies. J Nucl Med. 2009;59:1360.
101. Siegrist PT, Husmann L, Knabenhans M, et al. (13)Nammonia myocardial perfusion imaging with a PET/CT scanner: impact on clinical decision making and costeffectiveness. Eur J Nucl Med Mol Imaging. 2008;35:889-895.
102. Vos FJ, Bleeker-Rovers CP, Kullberg BJ, et al. Cost-effectiveness of routine (18)F-FDG PET/CT in high-risk patients with grampositive bacteremia. J Nucl Med. 2011;52:1673-1678.
103. Becerra Nakayo EM, Garc?́a Vicente AM, Soriano Castrejó n AM, et al. Analysis of cost-effectiveness in the diagnosis of fever of unknown origin and the role of (18)F-FDG PET-CT: a proposal of diagnostic algorithm. Rev Esp Med Nucl. 2012;31:178-186.